PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · News & media

Eli Lilly to sell Zepbound directly to consumers without insurance

News & media3:00Aug 2024

Today’s cheapest Zepbound$348/mo at Lemonaid Health, medication and membership billed separately.Compare all Zepbound prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

This report covers announcements from Eli Lilly and Pfizer about letting customers buy medications directly from the drug makers. Reporter the speaker says the change removes the middleman and that direct access to Big Pharma has essentially been unheard of until now. An unnamed commentator in the segment says companies likely see it as a way to raise profit margins, while consumers welcome the convenience.

Published by Eyewitness News ABC7NY on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

According to the report, Eli Lilly is now selling a new version of its weight loss drug Zepbound straight to consumers, in response to high demand and widespread shortages of Zepbound and similar drugs such as Wegovy. Lilly CEO another speaker tells Good Morning America that the company is working to build more supply. In the meantime, he says, it can release vial forms of the 2 and a half milligram and 5 milligram doses. The report also describes Pfizer's new program, PfizerForAll, which offers telehealth doctors, vaccination scheduling and home delivery of 16 medications for conditions including certain cancers, arthritis, Crohn's disease and Covid-19.

The segment also raises caution. A guest advises consumers to check that a supplier is ethical and prescribes legitimate, not counterfeit, drugs. The report closes by saying President Joe another speaker is pleased Lilly is offering direct access to Zepbound but wants drug companies to do more to lower prices overall.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:00 The report says Eli Lilly and Pfizer announced programs that let customers buy drugs directly from the companies, which could ease access to Zepbound.
  2. 0:30 A commentator says companies may see direct sales as a way to raise profit margins, while consumers welcome the convenience.
  3. 1:00 Lilly CEO another speaker says the company is working on more supply and can now release vial forms of the 2 and a half milligram and 5 milligram doses.
  4. 1:31 According to the report, Pfizer's program offers telehealth doctors, vaccination scheduling and home delivery of 16 medications.
  5. 2:02 The report says the FDA warned last month about adverse events, some needing hospitalization, possibly tied to dosing errors with compounded semaglutide injectables.
  6. 2:33 The report says President another speaker welcomes Lilly's direct access to Zepbound but wants drug companies to lower prices across the board.

Key moments

Tap one to play from there.

  1. 0:00 Introduction
  2. 0:46 Dose change
  3. 2:16 Wrapping up

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Zepbound

Questions this video answers

What Zepbound doses is Eli Lilly selling directly to consumers?

According to the video, Lilly CEO another speaker says the company can now release vial forms of the 2 and a half milligram and 5 milligram doses. He says this comes while Lilly works to build more supply amid shortages.

What did the FDA warn about compounded semaglutide?

The report says the FDA issued a warning last month after reports of adverse events, some requiring hospitalization. These may be related to overdoses caused by dosing errors with compounded semaglutide injectable products.

What is Pfizer's direct to consumer program?

The video says Pfizer launched PfizerForAll, which offers independent telehealth doctors, vaccination scheduling and home delivery of 16 medications. The conditions mentioned include certain cancers, various forms of arthritis, Crohn's disease and Covid-19.

What did President another speaker say about Zepbound direct sales?

According to the report, another speaker said he is pleased to see Eli Lilly offering direct to consumer access to Zepbound. He also said drug companies need to do more to lower their prices across the board.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Zepbound without insurance: every dose priced, and what the vial changes

    Without insurance, Zepbound costs $299 a month at the 2.5 mg starting dose and $399 at 5 mg, bought direct from Lilly. From 7.5 mg up the vial and the KwikPen are both $449 a month as long as each refill arrives within 45 days of the last; miss that window and it is $499 at 7.5 mg and $699 from 10 mg. That replaces a list price Lilly itself puts at $499 to $1,086.37 per fill. A year of 13 four-week fills at the trial doses is about $5,800 on refills kept on time and $9,087 at the regular price. Compounded tirzepatide, which is not FDA-approved, starts at $69 a month on our board.

  • How to get Zepbound: who qualifies, who prescribes it, and the four ways to pay

    Zepbound is a prescription drug approved for adults with obesity, or overweight with at least one weight-related condition, which the trials defined as a BMI of 30, or 27 with a comorbidity. Any licensed prescriber can write it, including online. Then it is a payment question with four answers: a commercial plan that covers it brings it to $25 with Lilly's card; Lilly sells it direct for $299 to $699 a month by dose; a plan that refuses can be appealed; and compounded tirzepatide, which is not FDA-approved, starts at $69 on our board.

  • What is Zepbound? Tirzepatide explained: what it treats, how it works, and what it costs

    Zepbound is Eli Lilly's brand of tirzepatide, a once-weekly injection that acts on two hormone receptors, GIP and GLP-1. The FDA label approves it, with diet and exercise, for weight reduction in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-5 trial it produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. Lilly sells it self-pay from $299 a month.

Next steps

Zepbound prices

Insurance

Find more like it

Dose changeCost and insurance

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV